The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production. While the ongoing geopolitical tensions continue to be a headwind, given the continuous need for innovative medical treatments (regardless of the state of the ec ...